Literature DB >> 3076661

Use of exercise Doppler for non-invasive haemodynamic optimization of dose and identification of poor responders to an oral anti-anginal agent. A double-blind dose-finding study of nisoldipine.

M Singer1, I F Trotman.   

Abstract

Nisoldipine, a new dihydropyridine calcium antagonist, was examined for its dose-related haemodynamic effects using exercise-induced changes in aortic blood flow as measured by Doppler ultrasound. Following a two-week placebo run-in, 24 patients with stable angina pectoris were assigned double-blind to one of three groups receiving doses ranging from 2.5-20 mg/day over 8 weeks, given once or twice daily. Doppler studies identified the low dose group as responding less well at the placebo phase compared to the other two groups. There was an overall improvement in percentage change of peak velocity and stroke distance with exercise at all doses, with a dose of 5 mg/day giving optimal benefit in both variables (P less than 0.05) and no additional benefit being seen on twice-daily dosage. Six patients reporting increased chest pain exhibited a significantly worse rise in peak velocity and a fall in stroke distance to exercise (P less than 0.05) whilst on active drug compared to those who responded favourably. Doppler ultrasound can be of benefit in the haemodynamic assessment of new drugs, the recognition of non-responders and the optimization of therapeutic regimes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3076661      PMCID: PMC2429006          DOI: 10.1136/pgmj.64.756.755

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

1.  Ascending aortic blood velocity and acceleration using Doppler ultrasound in the assessment of left ventricular function.

Authors:  E D Bennett; S A Barclay; A L Davis; D Mannering; N Mehta
Journal:  Cardiovasc Res       Date:  1984-10       Impact factor: 10.787

2.  Monitoring of changes in cardiac output by transcutaneous aortovelography, a non-invasive Doppler technique: comparison with thermodilution.

Authors:  A Distante; E Moscarelli; D Rovai; A L'Abbate
Journal:  J Nucl Med Allied Sci       Date:  1980 Jul-Dec

3.  A dose-ranging, placebo-controlled, double-blind trial of nisoldipine in effort angina: duration and extent of antianginal effects.

Authors:  J Lam; B R Chaitman; P Crean; R Blum; D D Waters
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

4.  Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552).

Authors:  S Kazda; B Garthoff; H Meyer; K Schlossmann; K Stoepel; R Towart; W Vater; E Wehinger
Journal:  Arzneimittelforschung       Date:  1980

5.  Noninvasive Doppler determination of cardiac output in man. Clinical validation.

Authors:  L L Huntsman; D K Stewart; S R Barnes; S B Franklin; J S Colocousis; E A Hessel
Journal:  Circulation       Date:  1983-03       Impact factor: 29.690

6.  Impaired left ventricular function in acute myocardial infarction assessed by Doppler measurement of ascending aortic blood velocity and maximum acceleration.

Authors:  N Mehta; D E Bennett
Journal:  Am J Cardiol       Date:  1986-05-01       Impact factor: 2.778

7.  Haemodynamic dose-response effects of intravenous nisoldipine in coronary artery disease.

Authors:  B Silke; M A Frais; P Muller; S P Verma; G Reynolds; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

8.  Effect of coronary artery disease on Doppler-derived parameters of aortic flow during upright exercise.

Authors:  R J Bryg; A J Labovitz; A A Mehdirad; G A Williams; B R Chaitman
Journal:  Am J Cardiol       Date:  1986-07-01       Impact factor: 2.778

9.  Improvement in exercise performance with nisoldipine, a new second-generation calcium blocker, in stable angina patients.

Authors:  L M Lopez; M R Rubin; J P Holland; J L Mehta
Journal:  Am Heart J       Date:  1985-11       Impact factor: 4.749

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.